J Biol Chem, Vol. 274, Issue 40, 28371-28378, October 1, 1999
Bombesin and Platelet-derived Growth Factor Induce
Association of Endogenous Focal Adhesion Kinase with Src in Intact
Swiss 3T3 Cells*
Eduardo Perez
Salazar
and
Enrique
Rozengurt§
From the Department of Medicine, School of Medicine and Molecular
Biology Institute, UCLA, Los Angeles, California 90095
 |
ABSTRACT |
Stimulation of quiescent Swiss 3T3 cells with
bombesin induces a rapid increase in the formation of complexes
between focal adhesion kinase (FAK) and Src family members, which can
be extracted with a buffer containing Triton, deoxycholate, and SDS but
not with a buffer containing Triton alone. An increase in complex formation between FAK and Src in response to bombesin could be detected within 1 min, reached a maximum after 10 min, and declined toward base-line levels after 60 min of bombesin treatment. Bradykinin, endothelin, and lysophosphatidic acid also stimulated FAK-Src complex
formation. Bombesin stimulated FAK/Src association through a
Ca2+ and phosphatidylinositol 3'-kinase-independent
pathway that requires the integrity of the actin filament network and
is partly dependent on functional protein kinase C. Treatment with the
selective Src kinase inhibitor PP-2 inhibited both FAK activation and
phosphorylation of FAK at Tyr577 induced by bombesin in
intact cells. Platelet-derived growth factor at low concentrations
(1-10 ng/ml) also induced FAK-Src complex formation via a pathway that
depended on the integrity of the actin cytoskeleton and
phosphatidylinositol 3'-kinase. Thus, G protein-coupled receptor
agonists and platelet-derived growth factor promote complex formation
between endogenous FAK and Src in attached cells through different
signal transduction pathways.
 |
INTRODUCTION |
Neuropeptides stimulate DNA synthesis and cell proliferation in
cultured cells and are implicated as growth factors in a variety of
fundamental processes including development, inflammation, tissue
regeneration, and tumorigenesis (1-3). In particular, bombesin and its
mammalian counterpart gastrin-releasing peptide bind to a G-protein
coupled receptor (GPCR)1 (4,
5) that promotes G
q-mediated activation of
isoforms of phospholipase C (6, 7) to produce two second messengers: inositol
1,4,5-trisphosphate that mobilizes Ca2+ from internal
stores and diacylglycerol that activates PKC (8-10). Subsequently,
bombesin induces activation of phosphorylation cascades including
p42MAPK/p44MAPK and p70S6K
(11-14), leading to increased expression of immediate early response genes, stimulation of cell cycle events, and subsequent cell
proliferation (10, 15-18).
The binding of bombesin to its heptahelical GPCR also induces rapid
tyrosine phosphorylation of multiple substrates in Swiss 3T3 cells (10,
19, 20), including activation and tyrosine phosphorylation of FAK (10,
21-23) and a transient increase in the kinase activity of Src (23, 24)
through different pathways (25). Tyrosine phosphorylation of FAK is
also increased by diverse signaling molecules that mediate cell growth
and differentiation, including bioactive lipids such as LPA (26-28),
polypeptide growth factors such as PDGF and insulin growth factor
(29-31), bacterial toxins (32, 33), activated variants of Src (34,
35), and extracellular matrix proteins (36-39). These results indicate
that FAK is a point of convergence in a variety of signal transduction pathways (40, 41). The importance of FAK-mediated signal transduction is underscored by recent experiments showing that this tyrosine kinase
is implicated in embryonic development (42) and in the control of cell
migration (43-45), proliferation (43, 46), and apoptosis (47-49).
Tyrosine phosphorylation plays a critical role in promoting the
recruitment of active signaling molecules into multiprotein signaling
networks (50). Because the major site of FAK autophosphorylation, Tyr397, is potentially a high affinity binding site for the
SH2 domain of Src, phosphorylation of this site could facilitate the
formation of a FAK-Src signaling complex in which both kinases are
active (35, 51). However, FAK tyrosine phosphorylation is not
sufficient for FAK/Src association, indicating the requirement for
additional signals (52). Transformation by oncogenic variants of Src or plating suspended cells onto fibronectin-coated dishes, an artificial paradigm of integrin receptor activation (53), induces complex formation between FAK and Src (54-59). In contrast, little is known about the assembly of FAK signaling complexes in response to
physiological concentrations of GPCR agonists in attached cells.
In the present study, we demonstrate that the mitogenic GPCR agonists
bombesin, endothelin, bradykinin, and LPA induce a rapid increase in
the formation of FAK-Src complexes in quiescent Swiss 3T3 cells.
Bombesin stimulates FAK/Src association through a Ca2+ and
PI 3-kinase-independent pathway that requires the integrity of the
actin filament network and is partly dependent on functional PKC. In
contrast, PDGF stimulates biphasic FAK/Src association via a PI
3-kinase-dependent pathway. Thus, GPCRs and tyrosine kinase
receptors promote complex formation between endogenous FAK and Src in
attached cells through different signal transduction pathways.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Stock cultures of Swiss 3T3 cells were
maintained in DMEM, supplemented with 10% fetal bovine serum in a
humidified atmosphere containing 10% CO2 and 90% air at
37 °C. For experimental purposes, Swiss 3T3 cells were plated in
100-mm dishes at 6 × 105 cells/dish in DMEM
containing 10% fetal bovine serum and used after 6-8 days when the
cells were confluent and quiescent.
Immunoprecipitation--
Quiescent cultures of Swiss 3T3 cells
were washed twice with DMEM, equilibrated in the same medium at
37 °C for at least 15 min, and then treated with bombesin or other
factors in DMEM for the times indicated. We used 2 × 106 cells grown in 100-mm dishes containing 10 ml of DMEM
for each experimental condition. The stimulation was terminated by
aspirating the medium and solubilizing the cells in 1 ml of ice-cold
buffer containing 50 mM HEPES, pH 7.4, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10%
glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, 100 mM NaF, and 1 mM
phenylmethylsulfonyl fluoride. In some experiments, the cells were
lysed in a buffer without added SDS and/or sodium deoxycholate, as
indicated in Fig. 1A.
Lysates were clarified by centrifugation at 14,000 rpm for 10 min, and
the pellets were discarded. After centrifugation, supernatants were
transferred to fresh tubes, and proteins were immunoprecipitated at
4 °C for 4 h with protein A-agarose linked to polyclonal
anti-Src family (SRC-2) antibodies as described previously (19, 21, 24,
60). Immunoprecipitates were washed three times with lysis buffer
containing 1% Triton, 1% deoxycholate, and 0.1% SDS and extracted in
2× SDS-PAGE sample buffer (200 mM Tris-HCl, pH 6.8, 1 mM EDTA, 6% SDS, 2 mM EDTA, 4%
2-mercaptoethanol, 10% glycerol), by boiling 10 min and resolved by
SDS-PAGE.
Western Blotting--
After SDS-PAGE, proteins were transferred
to Immobilon membranes. After transfer, membranes were blocked using
5% nonfat dried milk in phosphate-buffered saline, pH 7.2, and
incubated for 2 h at 22 °C with the anti-FAK Ab (C-20) (0.1 µg/ml), anti-Tyr(P) Ab (PY20) (0.2 µg/ml), or
anti-FAK-Tyr(P)577 (0.1 µg/ml), as indicated. The
membranes were washed three times with phosphate-buffered saline, pH
7.2, 0.1% Tween 20 and then incubated with secondary antibodies
(horseradish peroxidase-conjugated donkey antibodies to rabbit, NA 934)
(1:5000) for 1 h at 22 °C. After washing three times with
phosphate-buffered saline, pH 7.2, 0.1% Tween 20, the immunoreactive
bands were visualized using ECL detection reagents. Autoradiograms were
scanned using a ScanJet 6100C/T scanner (Hewlett Packard), and the
labeled bands were quantified using the Multi-Analyst software program
(Bio-Rad).
In Vitro Kinase Assay--
FAK immunoprecipitates were washed
three times with lysis buffer, two times with lysis buffer without
added SDS and sodium deoxycholate, and twice with FAK kinase buffer (20 mM HEPES, pH 7.35, 3 mM MgCl2).
Then the pellets were dissolved in 40 µl of kinase buffer
supplemented with 1 µM PP-2 to eliminate
transphosphorylation of FAK by co-immunoprecipitated Src during the
in vitro kinase assays, as recently described (23). The
reactions were started by adding 10 µCi of
[
-32P]ATP, carried out at 30 °C for 10 min, and
stopped on ice by adding EDTA to a final concentration of 10 mM. After centrifugation, the pellets were washed twice
with lysis buffer containing 5 mM EDTA, extracted for 5 min
at 95 °C in 2× SDS-PAGE sample buffer, and analyzed by SDS-PAGE.
The gels were fixed and dried, and autoradiography was performed at
80 °C. Autoradiograms were scanned using a ScanJet 6100C/T scanner
(Hewlett Packard), and the labeled band was quantified using the
Multi-Analyst software program (Bio-Rad).
Materials--
Bombesin, endothelin, bradykinin, LPA,
cytochalasin D, and GF I were obtained from Sigma. Recombinant PDGF (BB
homodimer), horseradish peroxidase-conjugated donkey antibodies to
rabbit (NA 934), and ECL reagent were from Amersham Pharmacia Biotech. Thapsigargin, wortmannin, and PP-2 were obtained from
Calbiochem-Novabiochem Ltd. FAK polyclonal Ab C-20, Src family
polyclonal Ab SRC-2, and anti-Tyr(P) monoclonal Ab PY20 were from Santa
Cruz Biotechnology, Inc. FAK-Tyr(P)577 was from
BIOSOURCE. All other reagents used were of the
purest grade available.
 |
RESULTS |
Bombesin Induces the Formation of a Complex between FAK and Src in
Swiss 3T3 Cells--
To determine whether bombesin induces the
formation of a complex between endogenous FAK and Src family members
(collectively referred to as Src, unless otherwise indicated) in Swiss
3T3 cells, quiescent cultures of these cells were treated with or
without bombesin for 10 min and lysed in buffer solutions containing
1% Triton in the absence or in the presence of deoxycholate with or
without SDS. The extracts were immunoprecipitated with anti-Src antibody SRC-2, which recognizes the C-terminal sequence (residues 509-533) of the family members Src, Yes, and Fyn (the Src family members expressed in fibroblasts), and the immune complexes were analyzed by SDS-PAGE followed by Western blotting with anti-FAK antibody. As illustrated in Fig.
1A (upper
panel), anti-FAK Western blotting of Src immunoprecipitates
revealed an association of endogenous FAK with Src when
bombesin-stimulated cells were lysed in a buffer containing Triton,
deoxycholate, and SDS. In contrast, we did not detect significant FAK
immunoreactivity in Src immunocomplexes when the cells were lysed in a
buffer containing 1% Triton (Fig. 1A), although a
substantial amount of Src was recovered in these lysates (Fig.
1A, lower panel), in agreement with
our previous results (23, 24) and with results obtained using cells
replated onto fibronectin (52). All subsequent experiments were
performed in Swiss 3T3 cells lysed with a buffer containing Triton,
deoxycholate, and SDS.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Bombesin induces FAK/Src association in the
Triton-insoluble fraction of Swiss 3T3 cells. A,
confluent and quiescent cells were treated at 37 °C with 2 nM bombesin for 10 min and subsequently lysed using a
buffer containing 1% Triton without or with 0.1% SDS and 1% sodium
deoxycholate (DOC), as indicated. FAK/Src association was
analyzed by immunoprecipitation using anti-Src polyclonal antibody
SRC-2 followed by Western blotting with anti-FAK Ab. B,
confluent and quiescent cells were treated for 10 min in the absence
( ) or in the presence (+) of 2 nM bombesin
(BOM). The cells were then lysed in a buffer containing 1%
Triton, 1% deoxycholate, and 0.1% SDS, and the lysates were analyzed
by immunoprecipitation with anti-FAK Ab followed by Western blotting
with anti-SRC2 Ab. The membranes were further analyzed by Western
blotting using anti-FAK Ab. The position of Src family proteins is
indicated by an arrow. The broad band under the
Src band is immunoglobulin heavy chain. The position of FAK is
indicated by an arrow. C, confluent and quiescent
cells were treated for 10 min in the absence ( ) or in the presence
(+) of 2 nM bombesin (BOM), 20 nM
bradykinin (BK), 10 nM endothelin
(END), and 2 µM LPA. The cells were then
lysed, and the lysates were analyzed by immunoprecipitation with
anti-Src Ab followed by Western blotting with anti-FAK Ab. The
membranes were further analyzed by Western blotting using anti-SRC-2
Ab. The positions of FAK and Src are indicated by the
arrows. The results are representative of at least three
independent experiments.
|
|
To substantiate further the existence of a FAK/Src interaction induced
by bombesin, cell lysates were immunoprecipitated using an antibody
directed against FAK followed by Western blot analysis to detect
interacting Src. As illustrated in Fig. 1B, Src
immunoreactivity was present in FAK immunoprecipitates produced from
bombesin-treated cells. Anti-FAK Western blotting of anti-FAK
immunoprecipitates confirmed that similar amounts of FAK protein were
recovered after stimulation with or without bombesin (Fig.
1B). We did not detect any FAK/Src association when cell
lysates obtained with buffer containing Triton, deoxycholate, and SDS
were immunoprecipitated with nonimmune antisera (data not shown). These
results indicate that bombesin induces the formation of a complex
between endogenous FAK and Src in intact Swiss 3T3 cells.
To examine whether activation of other GPCRs also increases FAK/Src
association, quiescent Swiss 3T3 cells were stimulated with 20 nM bradykinin, 10 nM endothelin, or 2 µM LPA for 10 min and lysed. The extracts were
immunoprecipitated with anti-Src antibody SRC-2, and the immune
complexes were analyzed by SDS-PAGE followed by Western blotting with
anti-FAK antibody. As shown in Fig. 1C (upper
panel), treatment with these GPCR agonists induced a marked
increase in the association of endogenous FAK with Src that was
comparable to that promoted by bombesin. Western blotting with anti-Src
antibody of anti-Src immunoprecipitates confirmed that similar amounts
of Src protein were recovered after treatment in the absence or in the
presence of these agonists (Fig. 1C, lower
panel).
Kinetics of Complex Formation between FAK and Src in Response to
Bombesin--
The kinetics of FAK/Src association stimulated by
bombesin in Swiss 3T3 cells is shown in Fig.
2A. An increase in complex formation between FAK and Src in response to bombesin could be detected
within 1 min, reached a maximum after 10 min, and declined toward
base-line levels after 60 min of bombesin treatment. In contrast,
tyrosine phosphorylation of FAK in response to bombesin was detectable
within seconds and persisted longer than FAK/Src association (Fig.
2B). These results imply that FAK tyrosine phosphorylation is not sufficient for FAK-Src complex formation in
bombesin-stimulated Swiss 3T3 cells.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Time course and dose response of
bombesin-induced FAK/Src association in Swiss 3T3 cells.
A, confluent and quiescent cells were treated at 37 °C
with 2 nM of bombesin for various times as indicated and
were subsequently lysed in a buffer containing Triton, deoxycholate,
and SDS. FAK-Src association was analyzed by immunoprecipitation using
anti-Src polyclonal antibody SRC-2 followed by Western blotting with
anti-FAK Ab. The membrane was analyzed further by Western blotting
using anti-SRC-2 Ab. B, confluent and quiescent cells were
treated at 37 °C with 2 nM bombesin for various times as
indicated and subsequently lysed. Tyrosine phosphorylation of FAK was
analyzed by immunoprecipitation using anti-FAK Ab followed by Western
blotting with anti-Tyr(P) antibody PY20. The membrane was analyzed
further by Western blotting using anti-FAK Ab. C,
confluent and quiescent cells were treated at 37 °C for 10 min
either in the absence or presence of various concentrations of bombesin
as indicated, and cell lysates were analyzed for FAK-Src association as
described above. The membrane was analyzed further by Western blotting
using anti-SRC-2 Ab. The positions of FAK and Src are indicated by the
arrows. The autoradiograms shown are representative of at
least three independent experiments. Quantification of FAK associated
with Src in A and C and tyrosine phosphorylation
of FAK in B was performed by scanning densitometry. Values
shown are the mean ± S.E. of at least three independent
experiments and are expressed as the percentage of the maximal increase
in FAK-Src association (A and B) or in tyrosine
phosphorylation of FAK (B) above control (unstimulated)
values.
|
|
Bombesin induced FAK-Src complex formation in a
concentration-dependent manner; half-maximal effect was
elicited at a concentration of 0.3 nM (Fig. 2C).
Immunoblotting with anti-Src antibody of anti-Src immunoprecipitates
verified that similar amounts of Src were recovered after different
conditions (times and concentrations) of bombesin treatment (Fig. 2,
A-C, lower panels).
Role of PKC and Ca2+ in the Association between FAK and
Src Induced by Bombesin--
Bombesin promotes rapid
G
q-mediated activation of phospholipase C to produce the
second messengers inositol 1,4,5-trisphosphate that mobilizes
Ca2+ from internal stores and diacylglycerol that activates
PKC. Consequently, we examined the role of PKC and Ca2+ in
bombesin-stimulated FAK-Src complex formation in Swiss 3T3 cells.
As shown in Fig. 3A, direct
stimulation of PKC with PDB for 10 min increased the association of FAK
with Src, indicating that PKC is a potential signaling pathway leading
to the formation of a complex between FAK and Src.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Role of PKC and Ca2+ in FAK/Src
association induced by bombesin in Swiss 3T3 cells.
A, confluent and quiescent cells were treated for 1 h
either in the absence ( ) or in the presence (+) of 3.4 µM GF 109203X. Cells were then incubated for a further 10 min either in the absence ( ) or in the presence (+) of 2 nM bombesin (BOM) or 200 nM PDB, as
indicated. The cells were then lysed, and the extracts were analyzed by
immunoprecipitation with anti-Src Ab followed by Western blotting with
anti-FAK Ab. The membranes were further analyzed by Western blotting
using anti-SRC-2 Ab. B, confluent and quiescent cells were
treated for 1 h either in the absence ( ) or in the presence (+)
of 3.4 µM GF 109203X. Cells were then incubated for a
further 10 min either in the absence ( ) or in the presence (+) of 2 nM bombesin (BOM) or 200 nM PDB, as
indicated. The cells were then lysed, and the extracts were analyzed by
immunoprecipitation using anti-Tyr(P) antibody PY20 followed by Western
blotting with anti-FAK Ab. C, Swiss 3T3 cells were
pretreated for 30 min in the absence ( ) or in the presence (+) of 30 nM thapsigargin (TG) and/or EGTA as indicated.
Cells were then incubated for a further 10 min either in the absence
( ) or in the presence (+) of 2 nM bombesin
(BOM), and cell lysates were analyzed for FAK/Src
association as described above. The membranes were further analyzed by
Western blotting using anti-SRC-2 Ab. The positions of FAK and Src are
indicated by the arrows. The autoradiograms shown are
representative of at least three independent experiments.
Quantification of FAK associated with Src in A and
C was performed by scanning densitometry. Values shown are
the mean ± S.E. of at least three independent experiments and are
expressed as the percentage of the maximal increase in FAK/Src
association above control (unstimulated) values.
|
|
To examine whether PKC was required for stimulation of FAK-Src complex
formation in response to bombesin, quiescent Swiss 3T3 cells were
incubated with or without 3.4 µM GF I (also known as
bisindolylmaleimide I or GF 109203X), a selective inhibitor of PKC (22,
61, 62), prior to stimulation with either PDB or bombesin. As
illustrated in Fig. 3A, treatment with GF I attenuated FAK-Src complex formation induced by bombesin and completely prevented the association between these kinases induced by PDB (Fig.
3A, upper panel). We verified that
similar amounts of Src were recovered after treatment with bombesin or
PDB in the absence or in the presence of GF I (Fig. 3A,
lower panel). In parallel cultures, treatment
with GF I did not prevent FAK tyrosine phosphorylation in response to
bombesin but abrogated PDB-induced FAK tyrosine phosphorylation (Fig.
3B). These results demonstrate that activation of PKC is
required for maximal FAK/Src association in response to bombesin in
Swiss 3T3 cells.
To investigate whether an increase in intracellular Ca2+
mediates FAK-Src complex formation induced by bombesin, quiescent Swiss 3T3 cells were treated with the tumor promoter thapsigargin in the
absence or in the presence of EGTA. Thapsigargin specifically inhibits
the endoplasmic reticulum Ca2+-ATPase and thereby depletes
Ca2+ from intracellular stores (63). Treatment with 30 nM thapsigargin for 30 min abolished the increase in
cytosolic Ca2+ induced by subsequently added bombesin
(results not shown) but did not block the increase in FAK-Src complex
formation induced by bombesin (Fig. 3C). Similarly,
chelation of extracellular Ca2+ with EGTA to prevent
Ca2+ influx did not affect FAK-Src complex formation in
response to bombesin. Furthermore, a combination of thapsigargin and
EGTA that completely prevents Ca2+ movements did not
inhibit bombesin-induced FAK-Src complex formation. We verified that
similar amounts of Src were recovered after treatment with thapsigargin
with or without EGTA in the absence or in the presence of bombesin
(Fig. 3C, lower panel). These results
indicate that bombesin stimulates FAK/Src association through a signal transduction pathway that is independent of Ca2+ influx and
mobilization in Swiss 3T3 cells.
Src Contributes to Maximal FAK Activation in Response to
Bombesin--
Recently, we demonstrated that GPCR agonists including
bombesin induce FAK activation (23), and the results presented above indicate that bombesin also stimulates the formation of a complex between FAK and Src in intact cells. Src associated with FAK is thought
to phosphorylate FAK at additional sites including Tyr576
and Tyr577, which are located in the kinase catalytic
domain of FAK and are required for maximal FAK activity (52, 64). Since
the precise mechanism by which GPCR agonists up-regulate FAK activity is not understood, we tested the hypothesis that Src
transphosphorylation of FAK contributes to maximal FAK activation
induced by bombesin in intact cells.
The pyrazolopyrimidine PP-2 is a novel and selective inhibitor of the
Src kinase family members (65). At concentrations that inhibit Src
kinase activity, PP-2 has only a slight effect on FAK kinase activity
(23) and thus provides a useful tool that discriminates between FAK and
Src. To examine the role of Src in the regulation of FAK activity,
cultures of Swiss 3T3 cells were treated in the absence or in the
presence of 10 µM PP-2, challenged with or without
bombesin, and then lysed. The extracts were immunoprecipitated with a
FAK Ab, and the resulting immunocomplexes were incubated with
[
-32P]ATP and analyzed by SDS-PAGE and autoradiography
to determine FAK autophosphorylation. PP-2 (at 1 µM) was
also added to the incubation mixture to eliminate transphosphorylation
of FAK by co-immunoprecipitated Src during the in vitro
kinase assays (23). As illustrated in Fig.
4A, treatment of intact cells
with PP-2 markedly inhibited (by 67%) the increase in FAK kinase
activity induced by bombesin stimulation. These results suggest that
Src mediates the increase in FAK activity induced by bombesin in intact cells, probably by phosphorylating
Tyr576/Tyr577 in the activation loop of FAK. To
examine directly this hypothesis, we determined whether bombesin
induces phosphorylation of endogenous FAK at Tyr577 in
Swiss 3T3 cells, using a site-specific antibody that recognizes the
phosphorylated state of this site. As shown in Fig. 4B,
bombesin induced a marked increase in the phosphorylation of FAK
Tyr577. Treatment of intact cells with 10 µM
PP-2 inhibited the phosphorylation of Tyr577 of FAK in
response to bombesin. We verified that similar amounts of FAK were
recovered after treatment with bombesin with or without PP-2 (Fig.
4B, lower panel).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
Role of Src activity in FAK/Src association
induced by bombesin in Swiss 3T3 cells. A, confluent
and quiescent cells were treated for 15 min either in the absence ( )
or in the presence (+) of 10 µM of PP2. Cells were then
incubated for a further 10 min either in the absence ( ) or in the
presence (+) of 2 nM bombesin (BOM), as
indicated. The cells were then lysed, the extracts were incubated with
anti-FAK Ab, and in vitro kinase reactions were performed as
described under "Experimental Procedures." The position of FAK is
indicated by an arrow. The autoradiogram shown is
representative of at least three independent experiments.
Quantification of the kinase activity of FAK was performed by scanning
densitometry. Values shown are the mean ± S.E. of at least three
independent experiments and are expressed as the percentage of the
maximal increase in the kinase activity of FAK above control
(unstimulated) values. B, confluent and quiescent cells were
treated for 15 min either in the absence ( ) or in the presence (+) of
10 µM of PP2. Cells were then incubated for a further 10 min either in the absence ( ) or in the presence (+) of 2 nM bombesin (BOM), as indicated. The cells were
then lysed, and the extracts were analyzed by immunoprecipitation using
anti-FAK antibody followed by Western blotting with
anti-FAK-Tyr(P)577 Ab. The membranes were further analyzed
by Western blotting using anti-FAK Ab. The positions of
FAK(P)577 and FAK are indicated by the arrows.
The autoradiogram shown is representative of at least three independent
experiments. Quantification of FAK(P)577 was performed by
scanning densitometry. Values shown are the mean ± S.E. of at
least three independent experiments and are expressed as the percentage
of the maximal increase in FAK(P)577 above control
(unstimulated) values. C, confluent and quiescent cells were
treated for 15 min either in the absence ( ) or in the presence (+) of
10 µM of PP2. Cells were then incubated for a further 10 min either in the absence ( ) or in the presence (+) of 2 nM bombesin (BOM), as indicated. The cells were
then lysed, and the extracts were analyzed by immunoprecipitation using
anti-FAK antibody followed by Western blotting with anti-Tyr(P)
antibody PY20. The membranes were further analyzed by Western blotting
using anti-FAK Ab. The positions of FAK(P) and FAK are indicated by the
arrows. The autoradiogram shown is representative of at
least three independent experiments. Quantification of tyrosine
phosphorylation of FAK was performed by scanning densitometry. Values
shown are the mean ± S.E. of at least three independent
experiments and are expressed as the percentage of the maximal increase
in tyrosine phosphorylation of FAK above control (unstimulated) values.
D, confluent and quiescent cells were treated for 15 min
either in the absence ( ) or in the presence (+) of 10 µM of PP2. Cells were then incubated for a
further 10 min either in the absence ( ) or in the presence (+) of 2 nM bombesin (BOM), as indicated. The cells were
then lysed, and the extracts were analyzed by immunoprecipitation using
anti-Src antibody followed by Western blotting with anti-FAK Ab. The
membranes were further analyzed by Western blotting using anti-SRC2-Ab.
The positions of FAK and Src are indicated by the arrows.
The autoradiogram shown is representative of at least three independent
experiments. Quantification of FAK associated with Src was performed by
scanning densitometry. Values shown are the mean ± S.E. of at
least three independent experiments and are expressed as the percentage
of the maximal increase in FAK-Src association above control
(unstimulated) values.
|
|
In parallel cultures, a similar treatment with PP-2 reduced (but did
not abolish) the increase in the overall tyrosine phosphorylation of
FAK (Fig. 4C). This is consistent with the hypothesis that PP-2 inhibits the phosphorylation of specific tyrosine residues of FAK
by Src (e.g. Tyr577, as shown in Fig.
4B) but does not interfere with FAK autophosphorylation (at
Tyr397). In agreement with this interpretation, treatment
of Swiss 3T3 cells with 10 µM PP-2 did not inhibit the
association of FAK with Src induced by bombesin (in fact, a small but
consistent enhancement was noticed), indicating that the catalytic
activity of Src is not necessary for the formation of this complex and
that Tyr397 is phosphorylated and available to associate
with Src in cells treated with PP-2 (Fig. 4D). We verified
that similar amounts of Src were recovered after treatment with
bombesin with or without PP-2 (Fig. 4D, lower
panel).
The results shown in Fig. 4 support the hypothesis that FAK-Src complex
formation induced by bombesin leads to the subsequent tyrosine
phosphorylation of endogenous FAK (by Src) at additional sites
(e.g. Tyr577) that are responsible for
up-regulating FAK activity in intact cells.
The Integrity of the Actin Cytoskeleton Is Essential for
Agonist-induced FAK/Src Association--
Treatment of the cells with
cytochalasin D, which caps the barbed end of actin filaments and
promotes their depolymerization, selectively inhibits the increase in
FAK tyrosine phosphorylation in response to bombesin and other GPCR
agonists (22, 24, 27-29, 32, 33) but does not prevent Src activation
in response to these agents (24). Here, we examined whether
cytochalasin D-mediated disruption of the actin
cytoskeleton interferes with the association of FAK with Src induced by bombesin.
Quiescent Swiss 3T3 cells were exposed for 2 h to increasing
concentrations of cytochalasin D and then stimulated with 2 nM bombesin for another 10 min. As shown in Fig.
5A, treatment with cytochalasin D completely blocked the association of FAK with Src
induced by bombesin in intact cells in a
concentration-dependent manner. Maximum inhibitory effect
was achieved at 2.4 µM, a concentration that completely
disrupts the actin cytoskeleton and the assembly of focal adhesions and
abolishes the increase in the overall tyrosine phosphorylation of FAK
(22). We verified that similar amounts of Src were recovered after
treatment with increasing concentrations of cytochalasin D (Fig.
5A, lower panel).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
Cytochalasin D prevents agonist-induced
FAK/Src association in Swiss 3T3 cells. A, confluent
and quiescent cells were treated for 2 h in the absence
(0) or in the presence of increasing concentrations of
cytochalasin D (CYT D), as indicated and then stimulated
without ( ) or with (+) 2 nM bombesin (BOM) for
a further 10 min. The cells were then lysed, and the lysates were
analyzed by immunoprecipitation with anti-Src SRC-2Ab followed by
Western blotting with anti-FAK Ab. The positions of FAK and Src are
indicated by the arrows. The autoradiogram shown is
representative of at least three independent experiments.
Quantification of FAK associated with Src was performed by scanning
densitometry. Values shown are the mean ± S.E. of at least three
independent experiments and are expressed as the percentage of the
maximal increase in FAK-Src association above control (unstimulated)
values. B, confluent and quiescent cells were treated for
2 h in the absence ( ) or in the presence (+) of 2.4 µM cytochalasin D (CYT D), as
indicated, and then stimulated with 2 nM bombesin for a
further 10 min. The cells were then lysed, and the extracts were
analyzed by immunoprecipitation using anti-FAK antibody followed by
Western blotting with anti-FAK-Tyr(P)577 Ab. The membranes
were further analyzed by Western blotting using anti-FAK Ab. The
positions of FAK(P)577 and FAK are indicated by the
arrows. The autoradiogram shown is representative of at
least three independent experiments. Quantification of
FAK(P)577 was performed by scanning densitometry. Values
shown are the mean ± S.E. of at least three independent
experiments and are expressed as the percentage of the maximal increase
in FAK(P)577 above control (unstimulated) values.
C, confluent and quiescent cells were treated for 2 h
in the absence ( ) or in the presence (+) of 2.4 µM
cytochalasin D (CYT D), as indicated, and then
stimulated with 20 nM bradykinin (BK), 10 nM endothelin (END), and 2 µM LPA
for 10 min. The cells were then lysed, and the lysates were analyzed
for FAK/Src association as described above. The membranes were further
analyzed by Western blotting using anti-SRC-2 Ab. The positions of FAK
and Src are indicated by arrows. The results are
representative of at least three independent experiments.
|
|
Pretreatment of quiescent Swiss 3T3 cells for 2 h with 2.4 µM cytochalasin D also prevented the increase in the
phosphorylation of Tyr577 in Swiss 3T3 cells (Fig.
5B). Treatment with cytochalasin D also prevented FAK-Src
complex formation in response to other GPCR agonists including
endothelin, bradykinin, and LPA (Fig. 5C). We verified that
similar amounts of Src were recovered after treatment with cytochalasin
D and the different agonists (Fig. 5C, lower panel).
PDGF Induces FAK/Src Association: Bell-shaped Dose Response and
Dependence on Functional PI 3-Kinase and Actin Cytoskeleton
Organization--
Previous studies from our laboratory demonstrated
that PDGF induces biphasic tyrosine phosphorylation of FAK through a
pathway dependent on the integrity of the actin cytoskeleton (29, 66). It is also known that PDGF stimulates association of Src with specific
tyrosine-phosphorylated residues of the PDGF receptor and promotes a
sustained increase in Src activity (67). Here, we examined the effect
of PDGF on the formation of FAK-Src complexes.
Lysates of quiescent cultures of Swiss 3T3 cells exposed to increasing
concentrations of PDGF (1-30 ng/ml) for 10 min were immunoprecipitated
with SRC-2 antibody, and the level of FAK in the resulting Src
immunoprecipitates was assessed by Western blot analysis. As
illustrated in Fig. 6A, PDGF
stimulated association of FAK with Src following a striking bell-shaped
dose-response relationship. A detectable increase was seen at 1 ng/ml
PDGF, and maximal effect was achieved at 5 ng/ml PDGF. At higher
concentrations of PDGF (e.g. 20 and 30 ng/ml), FAK-Src
complex formation was reduced sharply. We confirmed that similar
amounts of Src were recovered after treatment with increasing
concentrations of PDGF (Fig. 6A, lower
panel).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
PDGF induces biphasic FAK/Src association via
a PI 3-kinase-dependent pathway in Swiss 3T3 cells.
A, confluent and quiescent cells were incubated for 10 min
at 37 °C either in the absence or in the presence of increasing
concentrations of PDGF, as indicated. The cells were then lysed, and
the lysates were analyzed by immunoprecipitation with anti-Src Ab
followed by Western blotting with anti-FAK Ab. B, confluent
and quiescent cells were treated for 30 min either in the absence ( )
or in the presence (+) of 60 nM wortmannin. Cells were then
incubated for a further 10 min either in the absence ( ) or in the
presence (+) of either 2 nM bombesin (BOM) or 5 ng/ml of PDGF. The cells were then lysed, and the lysates were analyzed
for FAK/Src association, as described above. C, confluent
and quiescent cells were treated for 2 h either in the absence
( ) or in the presence (+) of 2.4 µM cytochalasin D
(CYT D). Cells were then incubated for a further 10 min
either in the absence ( ) or in the presence (+) of 5 ng/ml of PDGF.
The cells were then lysed, and lysates were analyzed as described
above. The membranes were further analyzed by Western blotting using
anti-SRC-2 Ab. The positions of FAK and Src are indicated by the
arrows. The autoradiograms shown are representative of at
least three independent experiments. Quantification of FAK associated
with Src was performed by scanning densitometry. Values shown are the
mean ± S.E. of at least three independent experiments and are
expressed as the percentage of the maximal increase in FAK-Src
association above control (unstimulated) values.
|
|
PDGF induces actin recruitment into membrane ruffles (68, 69) and
tyrosine phosphorylation of FAK (30) via a PI
3-kinase-dependent pathway, but the contribution of this
pathway to FAK-Src complex formation induced by PDGF was unknown. To
determine the role of PI 3-kinase in the association between FAK and
Src induced by PDGF in Swiss 3T3 cells, quiescent cultures of these
cells were pretreated for 30 min with wortmannin (60 nM),
which binds to and inhibits the catalytic (110-kDa) subunit of PI
3-kinase (70, 71) and then stimulated for 10 min with 5 ng/ml PDGF. To
verify the selectivity of the effect of wortmannin under our
experimental conditions, parallel cultures of Swiss 3T3 cells were also
stimulated with bombesin, which does not increase the levels of
phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol
3,4,5-trisphosphate in these cells (72). As shown in Fig.
6B, treatment with wortmannin prevented PDGF-induced FAK-Src
complex formation but had only a slight effect on the association of
FAK with Src induced by bombesin. We verified that similar amounts of
Src were recovered after treatment with bombesin or PDGF in the absence
or presence of wortmannin (Fig. 6B, lower
panel).
Given that PI 3-kinase induces Rac-dependent reorganization
of actin cytoskeleton into membrane ruffles (73, 74), leading to
formation of focal contacts (75), we examined whether disruption of the
actin cytoskeleton interferes with FAK-Src complex formation in
response to PDGF. Quiescent Swiss 3T3 cells were pretreated with 2.4 µM cytochalasin D for 2 h and then stimulated with 5 ng/ml PDGF for another 10 min. As shown in Fig. 6C,
treatment with cytochalasin D completely blocked FAK-Src complex
formation in response to PDGF. Similar amounts of Src were recovered
after treatment with cytochalasin D in the absence or presence of PDGF (Fig. 6C, lower panel).
 |
DISCUSSION |
The results presented here demonstrate that stimulation with
bombesin, other GPCR agonists (endothelin, bradykinin, and LPA), and
PDGF promotes the formation of FAK-Src complexes in Swiss 3T3 cells.
Association of Src with phosphorylated FAK has been demonstrated
previously in v-Src-transformed cells and in cells replated on
fibronectin-coated dishes, an assay of integrin receptor activation
(54, 56, 57, 59). Our results show that bombesin, at nanomolar
concentrations, induced complex formation between endogenous FAK and
Src in attached cells i.e. without overexpressing any of
these components and without subjecting the cells to detachment and
subsequent replating.
The kinase activity of Src kinase family members (such as Src, Yes, and
Fyn) is repressed when a key tyrosine residue in the carboxyl-terminal
region (corresponding to Tyr527 of the chicken protein) is
phosphorylated by Csk (reviewed in Ref. 50). Phosphorylation at
Tyr527 creates a binding site for Src SH2 domain and allows
an intramolecular interaction that locks Src in an inactive
conformation. Our previous results demonstrated that bombesin induces a
very rapid (peaking at 30-40 s) and transient activation of Src in
Swiss 3T3 cells (24) probably via dephosphorylation of
Tyr527 by a tyrosine phosphatase. Src activity returned to
base line levels after 2 min of incubation (24). In contrast, the
results presented here demonstrate that complexes between Src and FAK persisted for at least 30 min. Given that competition for the SH2
and/or SH3 domains of Src by high affinity allosteric ligands is an
alternative mechanism that promotes enzymatic activation of this kinase
(50, 76), the association of Src to FAK would lead to the formation of
a molecular complex in which Src kinases are active. Taken together,
our results suggest that GPCR agonists induce Src activation via at
least two different mechanisms in Swiss 3T3 cells.
Recently, we demonstrated that GPCR agonists including bombesin induce
FAK activation (23), but the precise mechanism by which GPCR agonists
up-regulate FAK activity is not understood. Src associated to FAK is
thought to phosphorylate FAK at additional sites including
Tyr576 and Tyr577, which are located in the
catalytic domain of FAK. The phosphorylation of these sites is required
for maximal FAK activity in vitro (52, 64). Since bombesin
stimulates complex formation between FAK and Src, we tested the
hypothesis that Src mediates FAK transphosphorylation and activation in
response to bombesin in intact cells. Our results show, for the first
time, that bombesin induces phosphorylation of Tyr577
of FAK and that the selective Src inhibitor PP-2, at a concentration that markedly reduced the phosphorylation of Tyr577, also
attenuated FAK activation in response to bombesin. These findings
suggest that Src mediates the increase in FAK activity induced by
bombesin in intact Swiss 3T3 cells.
Src plays a critical role in FAK signaling including migration and
apoptosis (44, 48), and FAK-Src complexes are implicated in the
tyrosine phosphorylation of the adaptor proteins p130CAS
and paxillin (77-79). It is therefore likely that FAK-Src complex formation is under tight regulation (52). Our results indicate that FAK
tyrosine phosphorylation is necessary but not sufficient for promoting
the formation of FAK-Src complexes, suggesting the need for additional
signals. For example, the kinetics of FAK tyrosine phosphorylation did
not coincide with FAK-Src complex formation in bombesin-stimulated
cells. Specifically, tyrosine phosphorylation of FAK was detectable
within seconds and persisted longer than FAK/Src association.
Furthermore, bombesin stimulated FAK tyrosine phosphorylation through a
signal transduction pathway that is largely independent of PKC
(e.g. Ref. 22 and Fig. 3B). However, we show here
that maximal FAK/Src association induced by bombesin requires a
functional PKC pathway. These findings support the hypothesis that FAK
tyrosine phosphorylation is not sufficient for triggering FAK/Src
association and suggests that a PKC-dependent signaling
pathway contributes to the formation of this complex.
Agonist-mediated increase in FAK tyrosine phosphorylation is
accompanied by profound alterations in the organization of the actin
cytoskeleton and in the assembly of focal adhesions (26, 27, 29,
80-82), the distinct areas of the plasma membrane where FAK is
localized (38, 83). Treatment of the cells with cytochalasin D, which
disrupts actin filaments, prevents the increase in FAK tyrosine
phosphorylation in response to multiple agents, suggesting a mechanism
involving the actin cytoskeleton and the focal adhesion plaques (22,
24, 27-29, 32, 33). In contrast, bombesin induces Src activation in
cytochalasin D-treated cells, indicating that FAK and Src activation
are mediated by different pathways (24).
Here we show that cytochalasin D profoundly inhibits FAK-Src complex
formation induced by bombesin and other agonists. Previous studies
demonstrated that treatment with cytochalasin D does not inhibit
production of inositol phosphates, Ca2+ mobilization, and
stimulation of PKC, Src, and p42MAPK/p44MAPK
activation in response to bombesin (22, 24, 27, 46, 60). Thus,
disruption of the actin cytoskeleton prevents FAK tyrosine phosphorylation, activation, and association with Src in a selective manner. These findings are consistent with a model in which FAK/Src association requires the integrity of the actin cytoskeleton and intact
focal adhesion plaques.
Our results demonstrate that PDGF induces a striking biphasic
association between FAK and Src, with maximal effect at only 5 ng/ml.
At higher concentrations of PDGF, complex formation between FAK and Src
is dramatically reduced. Previous studies demonstrated that PDGF, at
low concentrations, stimulates PI 3-kinase activity and causes
accumulation of actin in membrane ruffles, while at high
concentrations, PDGF induces actin disorganization (29). PI 3-kinase
activity is required for PDGF-induced formation of membrane ruffles
(69) and for the increase in tyrosine phosphorylation of FAK (30, 66).
Here, we show that the increase in complex formation between FAK and
Src induced by PDGF requires functional PI 3-kinase and an intact actin
cytoskeleton. We hypothesize that the stimulatory limb of the
bell-shaped dose-response curve of PDGF-stimulated FAK/Src association
is mediated by a PI 3-kinase-dependent pathway, whereas the
inhibitory limb is caused by PDGF-induced disorganization of the actin
cytoskeleton. Interestingly, bombesin does not increase the levels of
phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol
3,4,5-trisphosphate in Swiss 3T3 cells (72), and, accordingly, our
results show that the PI 3-kinase inhibitor wortmannin did not prevent
FAK/Src association promoted by this GPCR agonist. We conclude that
there are PI 3-kinase-dependent and -independent pathways
leading to FAK/Src association in the same cell.
In conclusion, our results demonstrate that stimulation of Swiss 3T3
cells with bombesin, endothelin, bradykinin, LPA, and PDGF induces a
rapid increase in the formation of a complex between FAK and Src.
Bombesin stimulates FAK/Src association through a Ca2+- and
PI 3-kinase-independent pathway that requires the integrity of the
actin filament network and is partly dependent on functional PKC. In
contrast, PDGF simulates biphasic FAK/Src association via a PI 3-kinase
pathway. Our results demonstrate, for the first time, that agonists of
either GPCRs or tyrosine kinase receptors promote FAK/Src association
in attached cells through different signal transduction pathways.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of a postdoctoral fellowship from Consejo Nacional de
Ciencia y Tecnologia, Mexico.
§
To whom all correspondence should be addressed: 900 Veteran Ave.,
Warren Hall Rm. 11-124, Dept. of Medicine, UCLA School of Medicine, Los
Angeles, CA 90095-178622. Tel.: 310-794-6610; Fax: 310-267-2399.
 |
ABBREVIATIONS |
The abbreviations used are:
GPCR, G-protein-coupled receptor;
DMEM, Dulbecco's modified Eagle's medium;
FAK, focal adhesion kinase;
LPA, lysophosphatidic acid, Ab, antibody;
PAGE, polyacrylamide gel electrophoresis;
PDB, phorbol
12,13-dibutyrate;
PDGF, platelet-derived growth factor;
PI 3-kinase, phosphatidylinositol 3-kinase;
PKC, protein kinase C;
PP-2, pyrazolopyrimidine 2;
SH2 and SH3, Src homology domain 2 and 3, respectively;
MAPK, mitogen-activated protein kinase;
S6K, S6
kinase.
 |
REFERENCES |
| 1.
|
Rozengurt, E.
(1986)
Science
234,
161-166[Abstract/Free Full Text]
|
| 2.
|
Rozengurt, E.
(1998)
J. Cell. Physiol.
177,
507-517[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Rozengurt, E.
(1999)
Curr. Opin. Oncol.
11,
116-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Battey, J. F.,
Way, J. M.,
Corjay, M. H.,
Shapira, H.,
Kusano, K.,
Harkins, R.,
Wu, W. J. M.,
Slattery, T.,
Mann, E.,
and Feldman, R. I.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
395-399[Abstract/Free Full Text]
|
| 5.
|
Zachary, I.,
and Rozengurt, E.
(1987)
J. Biol. Chem.
262,
3947-3950[Abstract/Free Full Text]
|
| 6.
|
Offermanns, S.,
Heiler, E.,
Spicher, K.,
and Schultz, G.
(1994)
FEBS Lett.
349,
201-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Hellmich, M. R.,
Battey, J. F.,
and Northup, J. K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
751-756[Abstract/Free Full Text]
|
| 8.
|
Nånberg, E.,
and Rozengurt, E.
(1988)
EMBO J.
7,
2741-2747[Medline]
[Order article via Infotrieve]
|
| 9.
|
Erusalimsky, J. D.,
Friedberg, I.,
and Rozengurt, E.
(1988)
J. Biol. Chem.
263,
19188-19194[Abstract/Free Full Text]
|
| 10.
|
Charlesworth, A.,
Broad, S.,
and Rozengurt, E.
(1996)
Oncogene
12,
1337-1345[Medline]
[Order article via Infotrieve]
|
| 11.
|
Mitchell, F. M.,
Heasley, L. E.,
Qian, N.-X.,
Zamarripa, J.,
and Johnson, G. L.
(1995)
J. Biol. Chem.
270,
8623-8628[Abstract/Free Full Text]
|
| 12.
|
Seufferlein, T.,
Withers, D. J.,
and Rozengurt, E.
(1996)
J. Biol. Chem.
271,
21471-21477[Abstract/Free Full Text]
|
| 13.
|
Seckl, M. J.,
Higgins, T.,
and Rozengurt, E.
(1996)
J. Biol. Chem.
271,
29453-29460[Abstract/Free Full Text]
|
| 14.
|
Withers, D. J.,
Seufferlein, T.,
Mann, D.,
Garcia, B.,
Jones, N.,
and Rozengurt, E.
(1997)
J. Biol. Chem.
272,
2509-2514[Abstract/Free Full Text]
|
| 15.
|
Rozengurt, E.,
and Sinnett-Smith, J.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
2936-2940[Abstract/Free Full Text]
|
| 16.
|
Rozengurt, E.,
and Sinnett-Smith, J.
(1988)
Prog. Nucleic Acids Res. Mol. Biol.
35,
261-295[Medline]
[Order article via Infotrieve]
|
| 17.
|
Albert, D. A.,
and Rozengurt, E.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1597-1601[Abstract/Free Full Text]
|
| 18.
|
Mann, D. J.,
Higgins, T.,
Jones, N. C.,
and Rozengurt, E.
(1997)
Oncogene
14,
1759-1766[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Zachary, I.,
Sinnett-Smith, J.,
and Rozengurt, E.
(1991)
J. Biol. Chem.
266,
24126-24133[Abstract/Free Full Text]
|
| 20.
|
Zachary, I.,
Gil, J.,
Lehmann, W.,
Sinnett-Smith, J.,
and Rozengurt, E.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4577-4581[Abstract/Free Full Text]
|
| 21.
|
Zachary, I.,
Sinnett-Smith, J.,
and Rozengurt, E.
(1992)
J. Biol. Chem.
267,
19031-19034[Abstract/Free Full Text]
|
| 22.
|
Sinnett-Smith, J.,
Zachary, I.,
Valverde, A. M.,
and Rozengurt, E.
(1993)
J. Biol. Chem.
268,
14261-14268[Abstract/Free Full Text]
|
| 23.
|
Rodríguez-Fernández, J. L.,
and Rozengurt, E.
(1998)
J. Biol. Chem.
273,
19321-19328[Abstract/Free Full Text]
|
| 24.
|
Rodríguez-Fernández, J. L.,
and Rozengurt, E.
(1996)
J. Biol. Chem.
271,
27895-27901[Abstract/Free Full Text]
|
| 25.
|
Rozengurt, E.
(1998)
Am. J. Physiol.
275,
G177-G182[Abstract/Free Full Text]
|
| 26.
|
Seufferlein, T.,
and Rozengurt, E.
(1994)
J. Biol. Chem.
269,
27610-27617[Abstract/Free Full Text]
|
| 27.
|
Seufferlein, T.,
and Rozengurt, E.
(1994)
J. Biol. Chem.
269,
9345-9351[Abstract/Free Full Text]
|
| 28.
|
Seufferlein, T.,
and Rozengurt, E.
(1995)
J. Biol. Chem.
270,
24343-24351[Abstract/Free Full Text]
|
| 29.
|
Rankin, S.,
and Rozengurt, E.
(1994)
J. Biol. Chem.
269,
704-710[Abstract/Free Full Text]
|
| 30.
|
Rankin, S.,
Hooshmand-Rad, R.,
Claesson-Welsh, L.,
and Rozengurt, E.
(1996)
J. Biol. Chem.
271,
7829-7834[Abstract/Free Full Text]
|
| 31.
|
Casamassima, A.,
and Rozengurt, E.
(1998)
J. Biol. Chem.
273,
26149-26156[Abstract/Free Full Text]
|
| 32.
|
Lacerda, H. M.,
Lax, A. J.,
and Rozengurt, E.
(1996)
J. Biol. Chem.
271,
439-445[Abstract/Free Full Text]
|
| 33.
|
Lacerda, H. M.,
Pullinger, G. D.,
Lax, A. J.,
and Rozengurt, E.
(1997)
J. Biol. Chem.
272,
9587-9596[Abstract/Free Full Text]
|
| 34.
|
Guan, J. L.,
and Shalloway, D.
(1992)
Nature
358,
690-692[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Parsons, J. T.,
and Parsons, S. J.
(1997)
Curr. Opin. Cell Biol.
9,
187-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Burridge, K.,
Turner, C. E.,
and Romer, L. H.
(1992)
J. Cell Biol.
119,
893-903[Abstract/Free Full Text]
|
| 37.
|
Lipfert, L.,
Haimovich, B.,
Schaller, M. D.,
Cobb, B. S.,
Parsons, J. T.,
and Brugge, J. S.
(1992)
J. Cell Biol.
119,
905-912[Abstract/Free Full Text]
|
| 38.
|
Hanks, S. K.,
Calalb, M. B.,
Harper, M. C.,
and Patel, S. K.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8487-8491[Abstract/Free Full Text]
|
| 39.
|
Schaller, M. D.,
and Parsons, J. T.
(1994)
Curr. Opin. Cell Biol.
6,
705-710[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Zachary, I.,
and Rozengurt, E.
(1992)
Cell
71,
891-894[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Rozengurt, E.
(1995)
Cancer Surv.
24,
81-96[Medline]
[Order article via Infotrieve]
|
| 42.
|
Ilic, D.,
Damsky, C. H.,
and Yamamoto, T.
(1997)
J. Cell Sci.
110,
401-407[Abstract]
|
| 43.
|
Gilmore, A. P.,
and Romer, L. H.
(1996)
Mol. Biol. Cell
7,
1209-1224[Abstract]
|
| 44.
|
Cary, L. A.,
Chang, J. F.,
and Guan, J. L.
(1996)
J. Cell Sci.
109,
1787-1794[Abstract]
|
| 45.
|
Illc, D.,
Furuta, Y.,
Kanazawa, S.,
Takeda, N.,
Sobue, K.,
Nakatsuji, N.,
Nomura, S.,
Fujimoto, J.,
Okada, M.,
Yamamoto, T.,
and Aizawa, S.
(1995)
Nature
377,
539-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Seufferlein, T.,
Withers, D. J.,
Mann, D.,
and Rozengurt, E.
(1996)
Mol. Biol. Cell
7,
1865-1875[Abstract]
|
| 47.
|
Xu, L. H.,
Owens, L. V.,
Sturge, G. C.,
Yang, X.,
Liu, E. T.,
Craven, R. J.,
and Cance, W. G.
(1996)
Cell Growth Differ.
7,
413-418[Abstract]
|
| 48.
|
Frisch, S. M.,
Vuori, K.,
Ruoslahti, E.,
and Chan-Hui, P. Y.
(1996)
J. Cell Biol.
134,
793-799[Abstract/Free Full Text]
|
| 49.
|
Hungerford, J. E.,
Compton, M. T.,
Matter, M. L.,
Hoffstrom, B. G.,
and Otey, C. A.
(1996)
J. Cell Biol.
135,
1383-1390[Abstract/Free Full Text]
|
| 50.
|
Pawson, T.
(1995)
Nature
373,
573-580[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Hanks, S. K.,
and Polte, T. R.
(1997)
BioEssays
19,
137-145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Schlaepfer, D. D.,
Jones, K. C.,
and Hunter, T.
(1998)
Mol. Cell. Biol.
18,
2571-2585[Abstract/Free Full Text]
|
| 53.
|
Burridge, K.,
and Chrzanowska-Wodnicka, M.
(1996)
Annu. Rev. Cell Dev. Biol.
12,
463-518[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Xing, Z.,
Chen, H. C.,
Nowlen, J. K.,
Taylor, S. J.,
Shalloway, D.,
and Guan, J. L.
(1994)
Mol. Biol. Cell
5,
413-421[Abstract]
|
| 55.
|
Cobb, B. S.,
Schaller, M. D.,
Leu, T. H.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
147-155[Abstract/Free Full Text]
|
| 56.
|
Schlaepfer, D. D.,
Hanks, S. K.,
Hunter, T.,
and van der Geer, P.
(1994)
Nature
372,
786-791[Medline]
[Order article via Infotrieve]
|
| 57.
|
Schaller, M. D.,
Hildebrand, J. D.,
Shannon, J. D.,
Fox, J. W.,
Vines, R. R.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
1680-1688[Abstract/Free Full Text]
|
| 58.
|
Eide, B. L.,
Turck, C. W.,
and Escobedo, J. A.
(1995)
Mol. Cell. Biol.
15,
2819-2827[Abstract]
|
| 59.
|
Schlaepfer, D. D.,
Broome, M. A.,
and Hunter, T.
(1997)
Mol. Cell. Biol.
17,
1702-1713[Abstract]
|
| 60.
|
Zachary, I.,
Sinnett-Smith, J.,
Turner, C. E.,
and Rozengurt, E.
(1993)
J. Biol. Chem.
268,
22060-22065[Abstract/Free Full Text]
|
| 61.
|
Toullec, D.,
Pianetti, P.,
Coste, H.,
Bellevergue, P.,
Grandperret, T.,
Ajakane, M.,
Baudet, V.,
Boissin, P.,
Boursier, E.,
Loriolle, F.,
Duhamel, L.,
Charon, D.,
and Kirilovsky, J.
(1991)
J. Biol. Chem.
266,
15771-15781[Abstract/Free Full Text]
|
| 62.
|
Yeo, E.-J.,
and Exton, J. H.
(1995)
J. Biol. Chem.
270,
3980-3988[Abstract/Free Full Text]
|
| 63.
|
Thastrup, O.,
Cullen, P. J.,
Drøbak, B. K.,
Hanley, M. R.,
and Dawson, A. P.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2466-2470[Abstract/Free Full Text]
|
| 64.
|
Calalb, M. B.,
Polte, T. R.,
and Hanks, S. K.
(1995)
Mol. Cell. Biol.
15,
954-963[Abstract]
|
| 65.
|
Hanke, J. H.,
Gardner, J. P.,
Dow, R. L.,
Changelian, P. S.,
Brissette, W. H.,
Weringer, E. J.,
Pollok, B. A.,
and Connelly, P. A.
(1996)
J. Biol. Chem.
271,
695-701[Abstract/Free Full Text]
|
| 66.
|
Casamassima, A.,
and Rozengurt, E.
(1997)
J. Biol. Chem.
272,
9363-9370[Abstract/Free Full Text]
|
| 67.
|
DeMali, K. A.,
and Kazlauskas, A.
(1998)
Mol. Cell. Biol.
18,
2014-2022[Abstract/Free Full Text]
|
| 68.
|
Wennström, S.,
Hawkins, P.,
Cooke, F.,
Hara, K.,
Yonezawa, K.,
Kasuga, M.,
Jackson, T.,
Claesson-Welsh, L.,
and Stephens, L.
(1994)
Curr. Biol.
4,
385-393[CrossRef][Medline]
[Order article v |